PEPG

Pepgen Inc.

A clinical-stage biotech working to treat severe neuromuscular diseases, PepGen builds "oligonucleotide" medicines designed to fix faulty genetic instructions, using its EDO platform of cell-penetrating peptides to ferry drugs into muscle and other hard-to-reach tissues. Its lead candidate, PGN-EDODM1, targets myotonic dystrophy type 1 and has earned Orphan Drug and Fast Track designations. Founded in 2018, the company's name combines "Pep" for its peptide delivery technology and "Gen" for the genetic diseases it tackles.